Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Future Oncology (London, England)|February 17, 2023
A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN studyAjay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, et al.
The Lancet. Oncology|November 17, 2018
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trialSuzanne Trudel, Nikoletta Lendvai, Rakesh Popat, et al.
British Journal of Haematology|March 20, 2024
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN studyAjay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, et al.
British Journal of Haematology|September 16, 2022
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN studyDouglas W Sborov, Muhamed Baljevic, Brandi Reeves, et al.
Acta Haematologica|March 5, 2025
ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia VeraJohn Mascarenhas, Prithviraj Bose, Christopher Hillis, et al.
American Journal of Hematology|April 16, 2024
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFINRebecca Silbermann, Jacob Laubach, Jonathan L Kaufman, et al.
Blood Cancer Journal|July 8, 2024
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFINAjai Chari, Jonathan L Kaufman, Jacob Laubach, et al.
The Lancet. Haematology|September 14, 2023
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trialPeter M Voorhees, Douglas W Sborov, Jacob Laubach, et al.
Blood|April 24, 2020
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trialPeter M Voorhees, Jonathan L Kaufman, Jacob Laubach, et al.
Transplantation and Cellular Therapy|December 9, 2022
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN TrialsSaurabh Chhabra, Natalie Callander, Nicole L Watts, et al.
Pageof 3